An overview of human anti-HIV-1 neutralizing antibodies against diverse epitopes of HIV-1
In this Review, we have addressed some recent developments in the discovery and
applications of anti-human immunodeficiency virus type− 1 (HIV− 1) broadly neutralizing …
applications of anti-human immunodeficiency virus type− 1 (HIV− 1) broadly neutralizing …
Contribution of the HIV-1 envelope glycoprotein to AIDS pathogenesis and clinical progression
A Valenzuela-Fernández, R Cabrera-Rodríguez… - Biomedicines, 2022 - mdpi.com
In the absence of antiviral therapy, HIV-1 infection progresses to a wide spectrum of clinical
manifestations that are the result of an entangled contribution of host, immune and viral …
manifestations that are the result of an entangled contribution of host, immune and viral …
[HTML][HTML] Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or
neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion …
neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion …
Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection
Broadly neutralizing antibodies (bnAbs) develop in a subset of HIV-1 infected individuals
over 2–3 years of infection. Infected infants develop plasma bnAbs frequently and as early …
over 2–3 years of infection. Infected infants develop plasma bnAbs frequently and as early …
B cell repertoire sequencing of HIV-1 pediatric elite-neutralizers identifies multiple broadly neutralizing antibody clonotypes
Introduction A limited subset of HIV-1 infected adult individuals typically after at least 2-3
years of chronic infection, develop broadly neutralizing antibodies (bnAbs), suggesting that …
years of chronic infection, develop broadly neutralizing antibodies (bnAbs), suggesting that …
The characteristics of the HIV-1 env glycoprotein are linked with viral pathogenesis
S Pérez-Yanes, M Pernas, S Marfil… - Frontiers in …, 2022 - frontiersin.org
The understanding of HIV-1 pathogenesis and clinical progression is incomplete due to the
variable contribution of host, immune, and viral factors. The involvement of viral factors has …
variable contribution of host, immune, and viral factors. The involvement of viral factors has …
[HTML][HTML] Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody
The structural and characteristic features of HIV-1 broadly neutralizing antibodies (bnAbs)
from chronically infected pediatric donors are currently unknown. Herein, we characterized a …
from chronically infected pediatric donors are currently unknown. Herein, we characterized a …
A rare mutation in an infant-derived HIV-1 envelope glycoprotein alters interprotomer stability and susceptibility to broadly neutralizing antibodies targeting the trimer …
The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is the sole
target of broadly neutralizing antibodies (bnAbs). Several mechanisms, such as the …
target of broadly neutralizing antibodies (bnAbs). Several mechanisms, such as the …
[HTML][HTML] Design and immunogenicity of an HIV-1 clade C pediatric envelope glycoprotein stabilized by multiple platforms
Various design platforms are available to stabilize soluble HIV-1 envelope (Env) trimers,
which can be used as antigenic baits and vaccine antigens. However, stabilizing HIV-1 …
which can be used as antigenic baits and vaccine antigens. However, stabilizing HIV-1 …
A rapid CRISPR/Cas12a-based assay for the detection of HIV-1 Indian Clade-C infections
Early detection of HIV-1 infection is crucial to initiate anti-retroviral therapy (ART) to suppress
viremia and disease progression. Herein, we developed a CRISPR/Cas12a-based HIV-1 …
viremia and disease progression. Herein, we developed a CRISPR/Cas12a-based HIV-1 …